Active substance
Results for the substance ropeginterferon alfa 2b
1 result
About this active substance
Ropeginterferon alfa-2b is a pegylated interferon used in the treatment of polycythemia vera, a chronic myeloproliferative disorder characterized by excessive production of blood cells. It works by modulating the immune response and inhibiting the proliferation of abnormal hematopoietic cells.
Ropeginterferon alfa-2b is administered as a subcutaneous injection, usually once every two weeks, and is preferred due to its long duration of action and improved safety profile compared to other interferons. It is commonly used to reduce hematocrit, control symptoms, and prevent thrombotic complications.
Common side effects include fatigue, flu-like symptoms, muscle pain, and depression. In rare cases, severe adverse reactions such as liver dysfunction or autoimmune disorders may occur. Regular monitoring of hematologic parameters and liver function is essential.
Ropeginterferon alfa-2b represents an advanced therapeutic option for patients with polycythemia vera, offering effective disease control and improved quality of life.
Ropeginterferon alfa-2b is administered as a subcutaneous injection, usually once every two weeks, and is preferred due to its long duration of action and improved safety profile compared to other interferons. It is commonly used to reduce hematocrit, control symptoms, and prevent thrombotic complications.
Common side effects include fatigue, flu-like symptoms, muscle pain, and depression. In rare cases, severe adverse reactions such as liver dysfunction or autoimmune disorders may occur. Regular monitoring of hematologic parameters and liver function is essential.
Ropeginterferon alfa-2b represents an advanced therapeutic option for patients with polycythemia vera, offering effective disease control and improved quality of life.